3.1.10.7. t-cell depleting induction therapy. prophylactic immunosuppression regimens many countries, particularly u.s., use potent t-cell depleting ‘induction’ treatments [243,244,246,335,340,342-345]. frequently, atg used prevention rejection immunological high-risk patients, supported meta-analysis , recommended guidelines . addition, potent biological agents used treatment severe, steroid resistant rejection episodes . use t-cell depleting antibodies immunological low-risk patients associated improved long-term outcomes increased risk severe opportunistic infections malignancy, particularly post-transplant lymphoproliferative disease [243,244,246,335,341-343]. centres use agents provide effective rejection prophylaxis order facilitate steroid withdrawal . recommendationstrength ratingt-cell depleting antibodies may used induction therapy immunologically high-risk patients.weak